



(51) International Patent Classification:

C12N 15/115 (2010.01) C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/US2017/036225

(22) International Filing Date:

06 June 2017 (06.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/347,004 07 June 2016 (07.06.2016) US

(71) Applicant: CEPHEID [US/US]; 904 Caribbean Drive, Sunnyvale, California 94089 (US).

(72) Inventors: LOKHOV, Sergey G.; 904 Caribbean Drive, Sunnyvale, California 94089 (US). GALL, Alexander A.; 904 Caribbean Drive, Sunnyvale, California 94089 (US). BARAZNENOK, Vera; 904 Caribbean Drive, Sunnyvale, California 94089 (US). VIAZOVKINA, Ekaterina V.; 904 Caribbean Drive, Sunnyvale, California 94089 (US). SHISHKINA, Irina; 904 Caribbean Drive, Sunnyvale, California 94089 (US). PERSING, David H.; 904 Caribbean Drive, Sunnyvale, California 94089 (US).

(74) Agent: HALIDAY, Emily M. et al.; WEAVER AUSTIN VILLENEUVE & SAMPSON LLP, P.O. Box 70250, Oakland, California 94612-0250 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,

SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: THERMOSTABLE POLYMERASE INHIBITOR COMPOSITIONS AND METHODS




FIG. 1A

(57) Abstract: The present disclosure relates to aptamers for temperature-dependent reversible inhibition of thermostable polymerase activity in order to improve sensitivity and specificity of various reactions and assays involving hot start polynucleotide synthesis. Methods for use of the aptamers and related compositions and kits are also provided.



## THERMOSTABLE POLYMERASE INHIBITOR COMPOSITIONS AND METHODS

### CROSS-REFERENCE TO RELATED APPLICATIONS

5     **[0001]** This application claims benefit of and priority to USSN 62/347,004 filed on June 7, 2016, which is incorporated herein by reference in its entirety for all purposes.

### CROSS-REFERENCE TO A SEQUENCE LISTING

10     **[0002]** This application includes a sequence listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. This ASCII copy, created on June 6, 2017, is named CPHDP012WO\_2017-06-06\_SeqList.txt and is 20795 bytes in size.

### TECHNICAL FIELD

15     **[0003]** This disclosure relates generally to nucleic acid inhibitors of thermostable polymerase activity, compositions comprising the inhibitors, and methods of their use. The nucleic acid inhibitors can adapt a secondary structure to reversibly inhibit thermostable polymerases, wherein the inhibitory activity is temperature dependent. The inhibitors are useful for methods and assays which include nucleic acid synthesis by the thermostable polymerase wherein the methods and assays benefit from utilizing a hot start method.

### 20     BACKGROUND

25     **[0004]** In vitro synthesis of nucleic acid target sequences, the foundation of numerous research assays and diagnostic products, often relies in part on the use of thermostable DNA polymerases and at least one oligonucleotide primer which is designed to specifically bind to a target nucleic acid substrate in a sample suspected of containing the target. While assays using the polymerase and primer(s) are designed to generate a specific sequence, it is well known that if the assay requires a period of time at a lower or ambient temperature, the target-specific primers may hybridize to non-target sequences or may form primer dimers, resulting in mispriming and the subsequent generation of non-specific products. Such products are undesirable as they can mask the product of interest  
30     as well as prematurely deplete the reaction mixture of necessary reagents.

**[0005]** A primary means for reducing the effects of mispriming is to reversibly inhibit the thermostable polymerase activity at lower temperatures where such mispriming is more likely to occur. Upon increasing the temperature of the polymerase reaction mix to temperatures approximating the optimal reaction temperature of the thermostable polymerase, the inhibitory activity is removed and the thermostable polymerase extends primer(s) bound to substrate nucleic acid molecules. This method of reversibly inhibiting a thermophilic DNA polymerase to prevent primer extension at lower temperatures is referred to as "hot-start."

10 **[0006]** Hot start may be accomplished by various physical, chemical, or biochemical methods. In a physical hot start, the DNA polymerase or one or more reaction components that are essential for DNA polymerase activity is not allowed to contact the sample DNA until all the components required for the reaction are at a high temperature (Horton, R.M. et al., *Biotechniques*, 16:42-43, 15 1994). Chemical hot start refers to a method which involves use of a DNA polymerase which is inactivated chemically but reversibly, such that the polymerase is inhibited at ambient temperatures and most active at higher temperatures (U.S. Pat. Nos. 5,773,258 and 6,183,998). Another way of implementing a hot start is to combine the DNA polymerase enzyme with an anti- 20 DNA polymerase antibody before adding it to the reagent. The antibody inhibits the polymerase activity at ambient temperature but at the high polymerase reaction temperature, the antibody is denatured and dissociates from the polymerase, allowing activation of the polymerase (Sharkey et al., *Bio/Technology*, 12:506-509 (1994); Kellogg *et al.*, *Biotechniques*, 16: 1134-1137 25 (1994)).

**[0007]** Another method for inhibiting thermophilic DNA polymerase at ambient temperatures involves the use of a nucleic acid aptamer which binds to and inhibits the DNA polymerase (US Patent No. 6,183,967). Aptamers are nucleic acid molecules having specific binding affinity to molecules through interactions 30 other than classic Watson-Crick base pairing. Various aptamers have been selected and designed to exhibit specificity and affinity for thermostable polymerases and have been shown to be capable of reversibly inhibiting the polymerases. As with other reversible inhibitors of thermostable polymerases, aptamers are designed to bind and inhibit a thermostable polymerase at ambient 35 temperatures. A subsequent increase in temperature results in the dissociation

of the aptamer from the thermostable polymerase to allow primer extension and/or nucleic acid amplification at high reaction temperatures.

**[0008]** When designing and selecting an inhibitory aptamer for use in a reaction requiring thermostable polymerase activity, it is important to generate aptamers that bind and inhibit the polymerase in the appropriate temperature range, such as the temperature range for optimal polymerase activity, but which also dissociate from the polymerase at temperatures which allow optimal thermostable polymerase activity at temperatures when selected primers are hybridized to a target nucleic acid substrate. Described herein are aptamers which can form a secondary structure and which can reduce generation of non-specific polymerase products in various assays which rely on thermostable polymerase activity but which can dissociate from the polymerase to facilitate target product generation and detection.

#### BRIEF SUMMARY

**[0009]** In one aspect, an aptamer is provided, wherein the aptamer comprises in a 5' to 3' direction: a first nucleotide sequence comprising TATAATTGCAAAATAA (SEQ ID NO:1) or a variant thereof or TTATTTTGCAATTATA (SEQ ID NO:2) or a variant thereof; a second nucleotide sequence comprising TTCTTAGCGTTT (SEQ ID NO:3) or a variant thereof, a third nucleotide sequence comprising SEQ ID NO:1 or a variant thereof or SEQ ID NO:2 or a variant thereof; and a fourth nucleotide sequence comprising SEQ ID NO:3 or a variant thereof, wherein the first sequence is complementary to the second sequence.

**[0010]** In some embodiments, the aptamer has a secondary structure wherein the first and third nucleotide sequences hybridize at temperatures below about 45°C, 42°C, 40°C, 39°C, or 38°C to form a stem and each of the second and third nucleotide sequences remain single stranded to form a loop, wherein the stem is positioned between the loops formed by the second and third nucleotide sequences.

**[0011]** In some embodiments, a covalent bond is present between the 5' end of the first sequence and the 3' end of the fourth sequence. In other embodiments, the covalent bond is a phosphodiester bond.

**[0012]** In some embodiments, the variant of SEQ ID NO:1 comprises 1, 2, 3 or 4 nucleotide substitutions and the third nucleotide sequence is complementary to

the variant of SEQ ID NO:2 wherein there are no mismatches between SEQ ID NO:1 and SEQ ID NO:2.

**[0013]** In some embodiments, the variant of SEQ ID NO:2 comprises 1, 2, 3 or 4 nucleotide substitutions and the first nucleotide sequence is complementary to the variant of SEQ ID NO:2 wherein there are no mismatches between SEQ ID NO:1 and SEQ ID NO:2.

**[0014]** In some embodiments, each of the first sequence and the third sequence is 14-18, 15-16 or 16-17 nucleotides in length. In still other embodiments, each of the first sequence and the third sequence is 14, 15, 16, 17 or 18 nucleotides in length. In a particular embodiment, each of the first sequence and the third sequence is 16 nucleotides in length.

**[0015]** In some embodiments, the first sequence comprises SEQ ID NO:1 and the second sequence comprises SEQ ID NO:2. In still other embodiments, the first sequence consists of SEQ ID NO:1 and the second sequence consists of SEQ ID NO:2.

**[0016]** In some embodiments, the first sequence is selected from the group consisting of SEQ ID NO:11-41 or a variant thereof, wherein the variant comprises 1, 2, 3 or 4 nucleotide substitutions. In other embodiments, the third sequence is the same length as the first sequence, and the third sequence is complementary to the first sequence, wherein there are no mismatches between the first sequence and the third sequence. In still other embodiments, the first sequence is selected from the group consisting of SEQ ID NO:11-41.

**[0017]** In some embodiments, the second sequence is identical to the fourth sequence along the entire length of the second and fourth sequences.

**[0018]** In some embodiments, each of the second and fourth sequences is 12 nucleotides in length.

**[0019]** In some embodiments, the second sequence comprises SEQ ID NO:3 and the fourth sequence comprises SEQ ID NO:3. In other embodiments, the second sequence consists of SEQ ID NO:3 and the fourth sequence consists of SEQ ID NO:3.

**[0020]** In some embodiments, the aptamer does not have a 5' end or a 3' end.

**[0021]** In some embodiments, the aptamer comprises a 5' end and a 3' end, wherein there is no covalent bond between 2 nucleotides within the first sequence or within the second sequence. In other embodiments, there is no covalent bond between nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6

and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, 13 and 14, 14 and 15 or 15 and 16 of SEQ ID NO:1 or of SEQ ID NO:2.

**[0022]** In some embodiments, the first sequence comprises SEQ ID NO:1 and the third sequence comprises SEQ ID NO:2, and there is no phosphodiester bond between nucleotides 8 and 9 of SEQ ID NO:1. In other embodiments, the first sequence comprises SEQ ID NO:2 and the third sequence comprises SEQ ID NO:1, and there is no phosphodiester bond between nucleotides 8 and 9 of SEQ ID NO:2.

**[0023]** In some embodiments, the first and third sequences of the aptamer are hybridized to each other in a double stranded configuration. In other embodiments, the first and third sequences of the aptamer are hybridized to each other in a double stranded configuration when the aptamer is in a solution at 25°C or at 37°C. In still other embodiments, the solution has a pH of about 6 to 8.

**[0024]** In some embodiments, both the second sequence and the fourth sequence are in a single stranded configuration. In other embodiments, both the second sequence and the fourth sequence are in a single stranded configuration when the aptamer is in a solution at 25°C or at 37°C. In still other embodiments, the solution has a pH of about 6 to 8.

**[0025]** In some embodiments, the aptamer has a melting temperature ranging from about 40°C to 50°C, 45°C to 65°C, 45°C to 60°C, 45°C to 55°C, 45°C to 50°C, 50°C to 65°C or 50°C to 60°C.

**[0026]** In some embodiments the aptamer comprises a sequence selected from the group consisting of SEQ ID NO:42-53 or a variant thereof wherein the variant comprises 1, 2, 3 or 4 nucleotide substitutions. In other embodiments, the aptamer comprises a sequence selected from the group consisting of SEQ ID NO:42-53. In still other embodiments, the aptamer has a 5' end and a 3' end.

**[0027]** In some embodiments, the 5' end of the aptamer comprises a phosphate group. In other embodiments, the 3' end of the aptamer comprises a phosphate group. In still other embodiments, the 5' and the 3' end each comprise a phosphate group.

**[0028]** In still other embodiments, the 3' end of the aptamer is linked to a 3' capping moiety. In yet another embodiment, the 5' end of the aptamer is linked to a 5' capping moiety. In still other embodiments, the 3' end of the aptamer is linked

to the 5' capping moiety and the 3' end of the aptamer is linked to the 5' capping moiety.

**[0029]** In some embodiments, the 5' capping moiety is selected from the group consisting of an amine group and an inverted deoxythymidine cap.

- 5 **[0030]** In some embodiments, the 3' capping moiety linked to the 3' end is selected from the group consisting of a phosphate, an inverted deoxythymidine cap and a propanediol spacer (C3).

**[0031]** In some embodiments, the aptamer comprises

- 10 CAAAATAATTCTTAGCGTTTTTATTTTGCAATTATATTCTTAGCGTTTTATAATT  
G-C3 (SEQ ID NO:106);  
CAAAATAATTCTTAGCGTTTTTATTTTGGAATTATATTCTTAGCGTTTTATAATT  
C-C3 (SEQ ID NO:107);  
GAAAATAATTCTTAGCGTTTTTATTTTCGAATTATATTCTTAGCGTTTTATAATT  
C-C3 (SEQ ID NO:108);  
15 CAATTATATTCTTAGCGTTTTATAATTGGAAAATAATTCTTAGCGTTTTTATTTT  
C-C3 (SEQ ID NO:109);  
CAATTATATTCTTAGCGTTTTATAATTGCAAAATAATTCTTAGCGTTTTTATTTT  
G-C3 (SEQ ID NO:110); or  
GAATTATATTCTTAGCGTTTTATAATTCGAAAATAATTCTTAGCGTTTTTATTTT  
20 C-C3 (SEQ ID NO:111). In other embodiments, there is no covalent bond  
between the first nucleotide and the last nucleotide of the aptamer comprising the  
sequence of one of SEQ ID NO:106-111.

- [0032]** In another aspect, an aptamer is provided wherein the aptamer  
comprises in a 5' to 3' direction a first polynucleotide comprising SEQ ID NO:4 or  
25 a variant thereof or SEQ ID NO:5 or a variant thereof, a second polynucleotide  
comprising SEQ ID NO:3 or a variant thereof, a third polynucleotide comprising  
SEQ ID NO:5 or a variant thereof or SEQ ID NO:4 or a variant thereof, and a  
fourth polynucleotide comprising SEQ ID NO:3 or a variant thereof or SEQ ID  
NO:5 or a variant thereof, wherein each of the second and fourth sequences are  
30 14-18 nucleotides in length, are equal in length, and are complementary to each  
other along their entire length; and wherein the aptamer comprises a 5' end and a  
3' end.

**[0033]** In some embodiments, the first polynucleotide and the third  
polynucleotide anneal to each other to form a stem.

**[0034]** In some embodiments, each of the second and fourth polynucleotides do not anneal to another region of the aptamer and each of the second and fourth polynucleotides form a first and a second loop.

5 **[0035]** In some embodiments, the stem is positioned between the first and second loops.

**[0036]** In some embodiments, the 3' end of the fourth sequence is covalently bound to the 5' end of the first sequence and there is no phosphodiester bond between 2 nucleotides within the fourth sequence.

10 **[0037]** In some embodiments, the 3' end of the fourth sequence is covalently bound to the 5' end of the first sequence and there is no phosphodiester bond between the last nucleotide of the third sequence and the first nucleotide of the fourth sequence.

**[0038]** In some embodiments, there is no phosphodiester bond between nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and  
15 9, 9 and 10, 10 and 11 or 11 and 12 of SEQ ID NO:3 in the fourth sequence.

**[0039]** In some embodiments, the first polynucleotide comprises the sequence selected from the group consisting of SEQ ID NOs:54-77.

**[0040]** In some embodiments, the first polynucleotide and the third polynucleotide are the same length. In still other embodiments, there is no  
20 mismatch between the first polynucleotide and the third polynucleotide.

**[0041]** In some embodiments, the first sequence is identical to the third sequence along the entire length of the first and third sequences.

**[0042]** In some embodiments, each of the first and third sequences is 12 nucleotides in length.

25 **[0043]** In some embodiments, the first sequence comprises SEQ ID NO:3 and the third sequence comprises SEQ ID NO:3. In other embodiments, the first sequence consists of SEQ ID NO:3 and the third sequence consists of SEQ ID NO:3.

**[0044]** In some embodiments, the aptamer comprises a sequence selected  
30 from the group consisting of SEQ ID NOs:82-105.

**[0045]** In some embodiments, the 5' end of the aptamer comprises a phosphate group. In other embodiments, the 3' end of the aptamer comprises a phosphate group. In still other embodiments, the 5' and the 3' end each comprise a phosphate group.



5 [0046] In still other embodiments, the 3' end of the aptamer is linked to a 3' capping moiety. In yet another embodiment, the 5' end of the aptamer is linked to a 5' capping moiety. In still other embodiments, the 3' end of the aptamer is linked to the 5' capping moiety and the 3' end of the aptamer is linked to the 5' capping moiety.

[0047] In some embodiments, the 5' capping moiety is selected from the group consisting of an amine group and an inverted deoxythymidine cap.

10 [0048] In some embodiments, the 3' capping moiety linked to the 3' end is selected from the group consisting of a phosphate, an inverted deoxythymidine cap and a propanediol spacer (C3).

[0049] In one aspect, a composition is provided comprising a thermostable polymerase and an aptamer according to any of the foregoing aspects and embodiments, wherein the aptamer inhibits the activity of the polymerase.

15 [0050] In some embodiments, the molar ratio of aptamer:polymerase in the composition ranges from about 1:1 to 20:1, 2:1 to 15:1, 5:1 to 20:1, 10:1 to 20:1, 12:1 to 18:1, 14:1 to 16:1, 1:1 to 10:1, 5:1 to 10:1, or 12:1 to 18:1. In other embodiments, the molar ratio of aptamer:polymerase in the composition is about 1:1, 2:1, 4:1, 5:1, 8:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1 or 20:1.

20 [0051] In some embodiments, the polymerase is selected from the group consisting of *Thermus aquaticus*, *Thermus thermophilus*, or *Thermus maritima*.

[0052] In some embodiments, the composition further comprises deoxyribonucleotide triphosphates and a divalent metal cation.

25 [0053] In some embodiments, the composition further comprises a forward primer. In other embodiments, the composition comprises both the forward primer and a reverse primer. In still other embodiments, the forward and/or reverse primer is specific for a target nucleic acid.

[0054] In some embodiments, the composition is a dried composition.

[0055] In some embodiments, the composition is a liquid composition.

30 [0056] In one aspect, a method for extending a primer is provided wherein the method comprises mixing the primer with a thermostable polymerase and an aptamer according to any of the foregoing aspects and embodiments to form a reaction mixture.

35 [0057] In some embodiments, the primer is specific for a target nucleic acid sequence.

**[0058]** In some embodiments, the method further comprises adding a reverse primer. In other embodiments, the reverse primer is specific for the target nucleic acid sequence.

5 **[0059]** In some embodiments, the method further comprises adding to the reaction mixture deoxyribonucleotide triphosphates and a divalent metal cation.

**[0060]** In some embodiments, the aptamer inhibits, reduces or eliminates the polymerase activity at a temperature below 45°C, 40°C, 37°C, 35°C, 32°C, or 30°C.

10 **[0061]** In one aspect, a kit is provided wherein the kit comprises a composition comprising an aptamer according to any of the foregoing aspects and embodiments and a thermostable polymerase.

**[0062]** In some embodiments, the kit further comprises a forward and a reverse primer, each of which is specific for a target nucleic acid sequence.

15 **[0063]** In some embodiments, the kit comprises primers and at least one probe for detecting and/or determining a sequence of the target nucleic acid sequence.

**[0064]** In some embodiments, the composition further comprises a forward oligonucleotide primer which is specific for the target nucleic acid sequence. In other embodiments, the composition further comprises a reverse oligonucleotide primer, which is specific for the target nucleic acid sequence.

20 **[0065]** In some embodiments, the kit further comprises a reverse transcriptase.

**[0066]** In some embodiments, the composition further comprises a reverse transcriptase.

**[0067]** In some embodiments, the composition is a dried composition.

**[0068]** In some embodiments, the composition is a liquid composition.

25 **[0069]** These and other objects and features of the invention will become more fully apparent when read in conjunction with the following detailed description.

#### BRIEF DESCRIPTION OF THE FIGURES

30 **[0070]** FIGS. 1A and 1B illustrate a closed aptamer having no 5' and 3' ends (1A) and an oligonucleotide sequence which can be synthesized to generate the closed aptamer shown in FIG. 1A (1B).

**[0071]** FIGS. 2A and 2B illustrate an aptamer having a 5' end (underlined C) and a 3' end (boxed G) (FIG. 2A) and an oligonucleotide sequence (FIG. 2B) which can be synthesized to generate the open aptamer shown in FIG. 2A. In this

illustration of an open aptamer having the predicted structure of a stem between two loops, there is no covalent bond between the 5'C and the 3'G.

**[0072]** FIGS. 3A and 3B illustrate a hairpin aptamer having a 3' overhang (FIG. 3A) and an oligonucleotide sequence (FIG. 3B) which can be synthesized to

5 generate the open predicted hairpin aptamer shown in FIG. 3A. The underline indicates the two portions of a loop sequence comprising TTCTTAGCGTTT (SEQ ID NO:3) wherein the absence of a covalent bond (e.g., phosphodiester bond) between two nucleotides within SEQ ID NO:3 allows formation of a predicted hairpin structure at ambient temperatures.

10 **[0073]** FIGS. 4A and 4B illustrate results of real time PCR reactions (Example 4) for the detection of 2 target sequences in genomic DNA. Reactions were run in the absence (FIG. 4A) and presence (FIG. 4B) of aptamers according to the present disclosure. The increase in fluorescence signifies the generation of the PCR products.

15 **[0074]** FIGS. 5A and 5B illustrate post-PCR melt curve analysis (Example 4) of real time PCR reactions shown in FIGS. 4A and 4B. Melt curve analysis of PCR products generated in the absence (FIG. 5A) and presence (FIG. 5B) shows that the presence of aptamer according to the present disclosure results in the generation of greater quantities of the target amplicons and lower quantities of  
20 non-specific products.

#### DETAILED DESCRIPTION

**[0075]** Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these  
25 embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.

**[0076]** The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature.

30 See, e.g.; A.L. Lehninger, *Biochemistry* (Worth Publishers, Inc., current addition); Morrison and Boyd, *Organic Chemistry* (Allyn and Bacon, Inc., current addition); J. March, *Advanced Organic Chemistry* (McGraw Hill, current addition); Remington: *The Science and Practice of Pharmacy*, A. Gennaro, Ed., 20<sup>th</sup> Ed.;

*Goodman & Gilman The Pharmacological Basis of Therapeutics*, J. Griffith Hardman, L. L. Limbird, A. Gilman, 10<sup>th</sup> Ed.

**[0077]** Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or  
5 intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1% to 8% is stated, it is intended that 2%, 3%, 4%, 5%, 6%, and 7% are also explicitly disclosed, as well as the range of values greater than or equal to 1% and the range of values less than or equal to 8%.

#### I. Definitions

10 **[0078]** It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise.

**[0079]** Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the  
15 art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the methodologies which are  
20 reported in the publications which might be used in connection with the invention.

**[0080]** The phrase "nucleic acid" or "polynucleotide" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are  
25 synthetic, naturally occurring, or non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids  
30 (PNAs).

**[0081]** As used herein, the term "thermostable polymerase" or "thermophilic polymerase" refers to an enzyme that is relatively stable to heat when compared, for example, to nucleotide polymerases from *E. coli*, and which catalyzes the template-dependent polymerization of nucleoside triphosphates. A "thermostable  
35 polymerase," will, e.g., retain enzymatic activity for polymerization and

exonuclease activities when subjected to the repeated heating and cooling cycles used in PCR. Preferably, a "thermostable nucleic acid polymerase" has optimal activity at a temperature above 45°C, or at a temperature ranging from 40°C to 80°C and more preferably from 55°C to 75°C. A representative thermostable polymerase enzyme isolated from *Thermus aquaticus* (Taq) is described in U.S. Pat. No. 4,889,818 and a method for using it in conventional PCR is described in Saiki et al., 1988, Science 239:487. Other thermostable DNA polymerases include, but are not limited to, DNA polymerases from thermophilic Eubacteria or Archaeobacteria, for example, *T. thermophilus*, *T. bockianus*, *T. flavus*, *T. rubber*, *Thermococcus litoralis*, *Pyrococcus furiosus*, *P. wosei*, *Pyrococcus* spec. KGD, *Thermatoga maritime*, *Thermoplasma acidophilus*, and *Sulfolobus* spec. Reverse transcriptases functional between 55-60° C. include, but are not limited to, MmLV reverse transcriptase, AMV reverse transcriptase, RSV reverse transcriptase, HIV-1 reverse transcriptase, and HIV-2 reverse transcriptase.

**[0082]** The term "aptamer" as used herein refers to a nucleic acid that has a specific binding affinity for a target molecule, such as a protein. Like all nucleic acids, a particular nucleic acid ligand may be described by a linear sequence of nucleotides (A, U, T, C and G), typically 30-75 nucleotides long. Aptamers may also be described in terms of regions of predicted secondary structure wherein a single strand portion of the aptamer is complementary to another single strand portion of the same aptamer and thereby can hybridize (anneal) to each other to form a duplex which is referred to herein as a "stem," and portions of the aptamer which are predicted not to hybridize with other portions of the same aptamer are referred to herein as "loops." Generally, each end of a loop is linked to an end of a stem thereby providing a loop configuration.

**[0083]** The term "capping moiety" refers to a moiety attached to the 3' or 5' end of an aptamer or other nucleic acid that changes the stability of the nucleic acid, prevents polymerase elongation of the nucleic acid, and/or increases the efficiency of nucleic acid dimer formation. By "cap structure" is meant chemical modifications, which have been incorporated into the ends of oligonucleotide (see, for example, Matulic-Adamic et al., U.S. Pat. No. 5,998,203). In non-limiting examples: a suitable 5'-cap can be one selected from the group comprising inverted abasic residue; 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide, 4'-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide;

phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.

**[0084]** In another non-limiting example, a suitable 3'-cap can be selected from a group comprising, 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties. For more details, see Beaucage and Iyer, 1993, Tetrahedron 49:1925, which is incorporated by reference herein.

**[0085]** A "variant" of a first nucleic acid sequence refers to a second nucleic acid sequence that has one or more nucleotide substitutions relative to the first nucleic acid sequence.

**[0086]** "Primers" refer to single-stranded oligonucleotides which are complementary to sequence portions on a template nucleic acid molecule separated by a variable number of nucleotides. Primers annealed to the template nucleic acid can be extended by covalent bonding of nucleotide monomers during amplification or polymerization of a nucleic acid molecule catalyzed by the thermostable polymerases. Typically, primers are from 12 to 35 nucleotides in length and are preferably from 15 to 20 nucleotides in length. Primers are designed from known parts of the template, one complementary to each strand of the double strand of the template nucleic acid molecule, lying on opposite sides of the region to be synthesized. Primers can be designed and synthetically prepared as is well known in the art.

**[0087]** The term used herein "forward primer" means a primer complementary to a strand of a nucleic acid sequence aligned in a 3' to 5' direction. The "reverse primer" has a complementary sequence to the other strand of the nucleic acid sequence.

5 **[0088]** "Template" as used herein refers to a double-stranded or single-stranded nucleic acid molecule, which serves a substrate for nucleic acid synthesis. In the case of a double-stranded DNA molecule, denaturation of its strands to form a first and a second strand is performed before these molecules may be used as substrates for nucleic acid synthesis. A primer, complementary  
10 to a portion of a single-stranded nucleic acid molecule serving as the template is hybridized under appropriate conditions and an appropriate polymerase may then synthesize a molecule complementary to the template or a portion thereof. The newly synthesized molecule may be equal or shorter in length than the original template.

15 **[0089]** A "target" or "target nucleic acid" refers to a single or double stranded polynucleotide sequence sought to be copied or amplified in a reaction which includes a polymerase and an oligonucleotide primer.

**[0090]** The term "hybridize" as used herein refers to the binding, duplexing, or hybridizing of a nucleic acid molecule preferentially to a particular nucleotide  
20 sequence. Hybridization generally involves the formation of hydrogen bonds between two single strands of a polynucleotide.

**[0091]** The term "complementary" as used herein refers to the capacity for precise pairing between two nucleotides; i.e., if a nucleotide at a given position of a nucleic acid is capable of hydrogen bonding (e.g., via standard Watson-Crick  
25 base pairing and Hoogsteen-type hydrogen bonding) with a nucleotide of another nucleic acid to form a canonical base pair, then the two nucleic acids are considered to be complementary to one another at that position.

Complementarity between two single-stranded nucleic acid molecules may be "partial." Complementarity is "complete," fully," or "100%" when there are no  
30 mismatches between the two single-stranded nucleotide sequences. "100% complementarity along the full length of the sequences" indicates that there are no mismatches between two nucleic acid strands which can hybridize and which are of identical length.

**[0092]** The term "oligonucleotide" as used herein refers to a sequence of  
35 nucleotide monomers, each bound to an adjacent nucleotide monomer by a

covalent bond. An “oligonucleotide” may also include a non-nucleotide subunit or a nucleotide analog within the sequence of nucleotide monomers wherein the non-nucleotide subunit or nucleotide analog is bound to an adjacent subunit, analog or nucleotide by a covalent bond. bound by means of a covalent bond.

- 5 The covalent bond between two adjacent nucleotide monomers in an oligonucleotide is a phosphodiester bond.

**[0093]** The term “dried” herein refers to a composition which has a water content of less than about 10%, 8%, 5%, 4%, 3%, 2%, 1% or 0.5%.

- [0094]** The “polymerase chain reaction” (“PCR”) is a reaction in which replicate  
10 copies are made of a target polynucleotide using one or more primers, and a catalyst of polymerization, such as a DNA polymerase, and particularly a thermally stable polymerase enzyme. Generally, PCR involves repeatedly performing a “cycle” of three steps: “melting,” in which the temperature is adjusted such that the DNA dissociates to single strands, “annealing,” in which  
15 the temperature is adjusted such that oligonucleotide primers are permitted to match their complementary base sequence using base pair recognition to form a duplex at one end of the span of polynucleotide to be amplified; and “extension” or “synthesis,” which may occur at the same temperature as annealing, or in which the temperature is adjusted to a slightly higher and more optimum  
20 temperature, such that oligonucleotides that have formed a duplex are elongated with a DNA polymerase. This cycle is then repeated until the desired amount of amplified polynucleotide is obtained. Methods for PCR amplification are taught, for example, in U.S. Pat. Nos. 4,683,195 and 4,683,202.

- [0095]** “Specificity” in primer extension or PCR amplification refers to the  
25 generation of a single, “specific” PCR product with the size and sequence predicted from the sequences of the primers and the genomic or transcribed region of nucleic acid to which the primers were designed to anneal in a base-complementary manner. “Nonspecific” PCR product has a size or sequence different from such prediction.

- 30 **[0096]** A “target nucleic acid” is that genomic or transcribed region of nucleic acid, the ends of which are base-complementary (with proper orientation) to primers included in a complete set of PCR reagents. A primer refers to a nucleic acid sequence, which is complementary to a known portion of a target nucleic acid sequence and which is necessary to initiate synthesis by DNA polymerase.  
35 “Proper orientation” is for the two primers to anneal to opposite strands of double-



stranded target nucleic acid with their 3' ends pointing toward one another. Such primers are said to target the genomic or transcribed sequence to the ends of which they are base-complementary. An "appropriate temperature", as referred to in the claims in regard to the PCR amplifications, indicates the temperature at which specific annealing between primers and a target nucleic acid sequence occurs.

**[0097]** "Oligonucleotide" refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are joined by a phosphodiester bond between the 3' position of the pentose of one nucleotide and the 5' position of the pentose of the adjacent nucleotide.

**[0098]** "Primer extension assay" refers to an in vitro method wherein a primer hybridized to a complementary sequence part of a single-stranded nucleic acid template molecule is extended by sequential covalent bonding of nucleotides to the 3' end of the primer forming a new DNA molecule complementary to the DNA template molecule. The primer extension method transforms a single-stranded nucleic acid template into a partially or completely double-stranded nucleic acid molecule. The primer extension method as used herein is a single step nucleic synthesis process without amplification of the copy number of the template nucleic acid molecule.

**[0099]** The term "modulate" or "regulate," as used herein, refers to a change in the activity of pyruvate dehydrogenase kinase (PDK). For example, modulation or regulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of the PDK.

**[0100]** The procedures disclosed herein which involve the molecular manipulation of nucleic acids are known to those skilled in the art. See generally Fredrick M. Ausubel et al. (1995), "Short Protocols in Molecular Biology," John Wiley and Sons, and Joseph Sambrook et al. (1989), "Molecular Cloning, A Laboratory Manual," second ed., Cold Spring Harbor Laboratory Press, which are both incorporated by reference.

## II. Aptamer Inhibitors of Polymerase Activity

**[0101]** The present disclosure provides reversible inhibitors of thermostable polymerases for use in reactions which require primer extension by the polymerase. These reversible inhibitors are aptamers, nucleic acids which are designed to adopt a secondary structure comprising a stem and a loop. The

aptamers are useful in reactions and assays that benefit from incorporating hot start and can improve the sensitivity and specificity of nucleic acid synthesis.

**[0102]** In some embodiments, the aptamer has a “dumbbell” structure (see, e.g., FIGS. 1A and 2A). The dumbbell aptamer can exist as a “closed” structure which has no 5′ or 3′ terminus (illustrated in FIG. 1A) due to ligation of the 5′ and 3′ ends of a synthesized oligonucleotide. For example, a closed dumbbell aptamer can be generated by synthesizing a linear oligonucleotide having the sequences provided herein, allowing annealing to form the predicted dumbbell structure, then ligating the 5′ and 3′. In some embodiments, the dumbbell aptamer is synthesized in a way to create 5′ and 3′ termini that are positioned adjacent to one another within the stem of the folded aptamer.

**[0103]** An example of a linear oligonucleotide which is predicted to fold into an aptamer with a stem and two loops is provided in FIGS. 1B and 2B, where 5′ and 3′ portions of the linear oligonucleotide hybridize to an internal complementary sequence in the same oligonucleotide to form a stem structure in which the 5′ and 3′ ends of the linear oligonucleotide are adjacent to one another. FIG. 1A shows an aptamer structure formed from the oligonucleotide sequence shown in FIG. 1B wherein the 5′ and 3′ ends of the oligonucleotide of FIG. 1B are ligated together. FIG. 2A shows an aptamer structure formed from the sequence shown in FIG. 2B wherein the 5′ and 3′ ends of the oligonucleotide are not ligated together, leaving the aptamer with a 5′ end and a 3′ end wherein the 5′ and 3′ ends are adjacent to one another within the predicted stem structure.

**[0104]** Accordingly, and with reference to FIG. 1A, an aptamer is provided in which a linear oligonucleotide can fold and anneal (hybridize) to comprise a first polynucleotide sequence comprising one strand of the stem (e.g., TTATTTTGCAATTATA (SEQ ID NO:2, written right to left in the illustration) in FIG. 1A), a second polynucleotide sequence which does not anneal to portions of the aptamer (e.g., TTCTTAGCGTTT (SEQ ID NO:3) to form a loop, a third polynucleotide sequence which is complementary to SEQ ID NO:1 and anneals to SEQ ID NO:1 in the appropriate conditions and temperature to form the stem (e.g., TATAATTGCAAATATA (SEQ ID NO:1) and a fourth polynucleotide sequence which also does not anneal to portions of the aptamer (e.g., TTCTTAGCGTTT (SEQ ID NO:3) to form a loop.

**[0105]** FIGS. 2A and 2B illustrate an “open” aptamer wherein the 5′ and 3′ ends are not ligated, i.e., the aptamer has a 5′ end and a 3′ end. Notably, the

nucleotides at the 5' and 3' ends are adjacent to one another within the stem of the predicted aptamer secondary structure. As shown in FIG. 2B, an oligonucleotide is synthesized and modified at its 3' end. In this particular embodiment, the 3' end is attached to a propanediol spacer (C3), preventing ligation of the 5' and 3' ends to form a closed aptamer. Upon heat denaturation and cooling, 5' and 3' portions of the oligonucleotide can hybridize to the internal complementary sequence of the oligonucleotide as illustrated in FIG. 2A.

**[0106]** The two loops (second and fourth polynucleotide sequences as described above and illustrated in FIGS. 1A and 2A) of the dumbbell aptamer can be identical to each other or can be minor variants of one another wherein a first loop differs from a second loop by 1 or 1 nucleotides. The loops comprise the polynucleotide sequence TTCTTAGCGTTT (SEQ ID NO:3) or a variant thereof wherein the variant contains 1 or 2 nucleotide substitutions within SEQ ID NO:3. Acceptable substitutions in the SEQ ID NO:3 are those which do not affect the reversible inhibitory activity of the aptamer by more than about 5% or 10% relative the aptamer in which the loop sequences each have SEQ ID NO:3.

**[0107]** The stem which is positioned between the two loops of the aptamer is a double-stranded structure (formed by hybridization or annealing of the first and third polynucleotide sequences as described above and illustrated in FIG. 1A) which is about 12 to 18 base pairs in length, however, the length of the stem can vary with the understanding that the variation may affect the temperature at which an aptamer dissociates from and no longer inhibits the polymerase activity. It is advantageous to have aptamers which vary with respect to the temperature at which they dissociate from the polymerase. Accordingly, the aptamers of the present disclosure include those that comprise a stem which is 12 to 16, 14 to 18, 14 to 17, 14 to 16, 15 to 16, 15 to 17, or 15 to 18 base pairs in length or is about 12, 13, 14, 15, 16, 17 or 18 base pairs in length. The stem is comprised of two single-stranded oligonucleotides of equal length such that the presently described aptamers are polynucleotides which comprise two single-strand oligonucleotide sequences which are 12 to 16, 14 to 18, 14 to 17, 14 to 16, 15 to 16, 15 to 17, or 15 to 18 nucleotides in length or about 12, 13, 14, 15, 16, 17 or 18 nucleotides in length and which are complementary to one another. In some embodiments, the two oligonucleotide sequences are hybridized via hydrogen bonds and no mismatches are present in the resultant stem of the aptamer. To form the aptamer comprising 2 loops and a stem, the 3' end of one single stranded stem

oligonucleotide sequence is covalently bonded to the 5' end of one of the two loops while the 3' end of the second single stranded stem oligonucleotide sequence is covalently bonded to the 5' end of the second of the two loops.

**[0108]** The aptamers comprising two loops as presently described can be in a closed or open form. In other words, in the closed form, there are no free ends of the aptamer polynucleotide. So, while the sequence maintains a 5' to 3' orientation as is well known in the art, the aptamer does not comprise a 5' end (e.g., 5' phosphate) or a 3' end (e.g., 3' hydroxyl). Instead, every nucleotide in the aptamer is bound to the adjacent neighbor by a covalent bond. In some embodiments, the covalent bond is a phosphodiester bond. In other embodiments, every covalent bond linking the nucleotide monomers in the aptamer is a phosphodiester bond. In an alternative embodiment, one strand of the aptamer stem comprises a non-nucleotide linking moiety such as a linker comprising DMT-ethane diol phosphoroamidite (C-2 spacer).

**[0109]** In some embodiments, the stem structure in the aptamer lacks a covalent bond between two of the nucleotides in only one of the strands of the stem. In these embodiments, the aptamer has a 5' end and a 3' end. As all nucleotides in the stem can remain hybridized to the opposite, fully complementary strand, the 5' and 3' ends remain adjacent to one-another when the aptamer is folded into its predicted secondary structure (see, e.g., FIG. 1A). In some embodiments, the 5' end comprises a phosphate group while the 3' end comprises a hydroxyl group. In alternative embodiments, the 5' end, the 3' end or both ends are linked to a capping moiety. The capping moiety may function to stabilize the aptamer and/or to prevent polymerization initiated at the 3' end of the aptamer. It is also possible that the lack of a covalent bond and/or the presence of a capping moiety may disrupt hydrogen bond(s) between nucleotides closest to the 5' and/or 3' end but this will not necessarily affect the inhibitory activity of the aptamer.

**[0110]** To synthesize a aptamer having two loops and a stem according to the present disclosure, a linear oligonucleotide is synthesized in a 3' to 5' direction using routine chemical synthesis methods. To generate a closed aptamer as described above (having no 5' or 3' free ends), the desired aptamer sequence is first synthesized then denatured by heating and slowly cooled to room temperature to allow the oligonucleotide to anneal to form an aptamer having the desired predicted dumbbell structure. For example, the synthesized

oligonucleotide can be denatured in a 5 mM HEPES-KOH buffer at pH 7.5 with 50 mL of a salt such as KCl at a temperature of about 95°C then slowly cooled (about 45 minutes to 1 hour) to room temperature.

**[0111]** Ligation of the 5' and 3' ends can be achieved by chemical or enzymatic means (see, e.g., Example 1) after synthesis, denaturation and annealing of the oligonucleotide as described above. Enzymatic ligation can be achieved through the use of T4 ligase wherein the 5' end of the synthesized oligonucleotide is phosphorylated and incubated with T4 ligase under appropriate conditions. Chemical ligation can be performed using, e.g. cyanogen bromide, or other methods routine in the art. In some embodiments, an oligonucleotide synthesized then first modified to place an amino group at the 5' end of the oligonucleotide. The 5'-modified oligonucleotide is then incubated with imidazole-HCl (pH 6.0) and 16.7 mg EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) to ligate the 5' and 3' ends together, forming an aptamer with the predicted structure of 2 loops and a stem wherein every nucleotide within the aptamer is covalently bonded to 2 adjacent nucleotides.

**[0112]** To generate an aptamer having free 5' and 3' ends, the desired aptamer sequence can be chemically synthesized above wherein the first and last nucleotides in the synthetic oligonucleotide are the nucleotides which will be adjacent to one-another within a single strand of the stem structure (as described above and shown in FIGS. 2A and 2B) but lacking a covalent bond (e.g. phosphodiester bond) between the 5' and 3' ends. In some embodiments, the 5' end lacks a phosphate group. The synthetic oligonucleotide will fold under appropriate conditions to have a predicted secondary structure with two loops separated by a stem in which there is a 5' end adjacent to a 3' end in one strand of the stem. The 5'-phosphate end can be attached to a capping moiety such as an amino group or other relevant capping moiety as described herein. The 3'-hydroxyl of the oligonucleotide can be attached to a capping moiety such as a propanediol spacer C3 or other relevant capping moiety as described herein (see Example 3). The aptamer can comprise a 5' cap, a 3' cap or both a 5' cap and a 3' cap. The presence of a 5' cap and/or 3' cap can inhibit ligation of the two ends of the oligonucleotide and can also inhibit polymerization of the oligonucleotide.

**[0113]** Aptamers which can bind to a polymerase and inhibit the polymerase activity as described above were designed to have 2 loops comprising the sequence TTCTTAGCGTTT (SEQ ID NO:3) as was determined by Yakimovich et

al. (2003, Biochem (Moscow), 68:228-235) as being responsible for binding to the polymerase and effecting inhibition of polymerase activity when bound. In some embodiments, the loop sequence of SEQ ID NO:3 has 1 or 2 nucleotide substitutions. The two loops are separated by a stem comprising two  
5 complementary sequences of equal length. Accordingly, the aptamer structure, an example of which is shown in FIG. 1, has two loops separated by a stem. While an exemplary single strand sequence of a stem is TATAATTGCAAAATAA (SEQ ID NO:1) and its complement is TTATTTTGCAATTATA (SEQ ID NO:2), it is contemplated that there may be 1, 2 or 3 base pair substitutions within the  
10 stem. Importantly, a substitution in one strand is always coupled with a complementary substitution in the complementary strand of the stem.

**[0114]** The stem sequence, such as that comprised of SEQ ID NO:1 paired with SEQ ID NO:2, is AT-rich. For example, the stem sequence is 12-18 base pairs in length wherein at least 14, 15, or 16 of those base pairs are A-T base pairs. In  
15 some embodiments, the stem positioned between the two loops is 16 base pairs in length and comprises 14 A-T base pairs and two G-C base pairs. The two G-C base pairs can be adjacent to one another.

**[0115]** As described above, the aptamer can lack a covalent bond between two nucleotides present in one of the strands within the stem portion. For example,  
20 the stem strand comprising SEQ ID NO:1 and SEQ ID NO:2 or variants thereof can lack a covalent bond between nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, 13 and 14, 14 and 15 or 15 and 16 of SEQ ID NO:1 or SEQ ID NO:2.

Accordingly, the aptamer which lacks a covalent bond between the 2 nucleotides  
25 comprises a single 5' terminus and a single 3' terminus. As noted above, an aptamer comprising a single 5' terminus and a single 3' terminus can be chemically synthesized as a single-stranded oligonucleotide comprising the entire sequence of the aptamer. In other words, the synthesized single strand oligonucleotide comprises a 5' portion of a first stem sequence comprising SEQ  
30 ID NO:1 or a variant thereof, a first loop sequence comprising SEQ ID NO:3 or a variant thereof, a second stem sequence comprising SEQ ID NO:2 or a variant thereof, a second loop sequence or a variant thereof and the remaining 3' portion of the first stem sequence comprising SEQ ID NO:1 or a variant thereof. Once synthesized as a single strand nucleotide it can fold under appropriate conditions  
35 to have two loops separated by a single stem, wherein one strand of the stem

does not have a covalent bond between 2 adjacent nucleotides. Not to be bound by theory, the lack of a covalent bond between 2 adjacent nucleotides in one strand of a predicted stem structure may allow flexibility, such as a bend, thereby facilitating interaction of each of the two predicted loop structures with the active site of the polymerase. The presence of two loops connected via a stem in the predicted dumbbell structure may increase the local concentration of the aptamer loops, leading to more efficient binding of the aptamer to the polymerase at lower temperatures such as about 25°C to 30°C. Accordingly, less aptamer may be needed in a reaction mixture to provide the desired hot start functionality.

- 10 **[0116]** It was also determined that by designing a dumbbell aptamer which comprises free 5' and 3' ends (lacks a covalent bond between two nucleotides of one strand of the stem), the aptamer is still able to inhibit polymerase activity of a thermostable polymerase at temperatures at or below about 30°C. Variations in the open dumbbell aptamer sequence can affect the temperature below which
- 15 polymerase activity is inhibited. In some embodiments, an open dumbbell aptamer inhibits polymerase activity at or below about 32°C, 35°C, 38°C, or 40°C. Particularly advantageous is the complete loss of polymerase activity inhibition by these open aptamer compositions at temperatures above 40°C, 45°C, 50°C or 55°C.
- 20 **[0117]** Table 1 below provides exemplary first and third sequences as described above with respect to aptamers which anneal to form a predicted dumbbell structure, wherein the first and third polynucleotide sequences of an aptamer are complementary to each other and can anneal to form the predicted stem structure. It is understood that each 5' and 3' end of the first and third
- 25 sequences below is ligated to one end of a loop structure. It is also understood that in some embodiments, one of the first and third polynucleotide sequences may lack a phosphodiester bond between two of the nucleotides within the first or third sequence. Additionally, any of these sequences predicted to form on strand of the predicted stem may have a nucleotide substitution at 1, 2 3 or 4 positions
- 30 in the sequence. Accordingly, the opposite strand which is predicted to anneal to this strand has a fully complementary sequence.

**Table 1**  
**Dumbbell Aptamer Stem Sequences**

SEQ ID NO	Sequence 5' → 3'
11	ATATTAAAAATTATA
12	TATAATTTTTTAATAT
13	ATATTAAAAATTATA
14	TATAATTTTTAATAT
15	ATATTAAAAATTATA
16	TATAATTTTTTAATAT
17	TTATTTTAAAAATTATA
18	TATAATTTTAAAAATAA
19	TTATTTTAAAAATTATA
20	TATAATTCCAAAATAA
21	TTATTTTGGAAATTATA
22	TATAATTGCAAAATAA
23	TTATTTTGCAATTATA
24	TATAATTCGAAAATAA
25	TTATTTTCGAATTATA
26	TTATTTTAAAAATTATA
27	TATAATTTTAAAAATAA
28	TTATTTTCCAATTATA
29	TATAATTGGAAAATAA
30	TTATTTTGCAATTATA
31	TATAATTGCAAAATAA
32	TTATTTTCGAATTATA
33	TATAATTCGAAAATAA
34	TATTTTAAAAATAT
35	ATATTTTAAAAATA
36	TATTTTAAAAATAT
37	ATATTTTAAAAATA
38	TATTTTAAAAATAT
39	ATATTTT-C2-spacer-TAAAAATA
40	TATTTTAAAAATAT
41	ATATTTT-C2-spacer-AAAAAATA

**[0118]** Table 2 below provides exemplary oligonucleotide sequences which can be synthesized and which are predicted to fold into an aptamer having two loops and a stem. The bolded nucleotides represent portions of a stem sequence which, when the oligonucleotide is folded as predicted, hybridizes to a second stem sequence indicated by the underlined portion.



**Table 2**  
**Dumbbell Aptamers Synthesized as Linear Oligonucleotides**

SEQ ID NO	Sequence 5' → 3'
42	<b>CAAAATAATTCTTAGCGTTTTTATTTTGAATTATATTCTTAGCGTTTATAATTG</b>
43	<b>CAATTATATTCTTAGCGTTTTATAATTGCAAAATAATTCTTAGCGTTTATTATTTG</b>
44	<b>TAAAATAATTCTTAGCGTTTTTATTTTAAAATTATATTCTTAGCGTTTATAATTT</b>
45	<b>CAAAATAATTCTTAGCGTTTTTATTTTGAATTATATTCTTAGCGTTTATAAATTC</b>
46	<b>GAAAATAATTCTTAGCGTTTTTATTTTCGAATTATATTCTTAGCGTTTATAAATTC</b>
47	<b>AAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCTTAGCGTTTATTATTTTA</b>
48	<b>CAATTATATTCTTAGCGTTTTATAATTGAAAATAATTCTTAGCGTTTATTATTTTC</b>
49	<b>GAATTATATTCTTAGCGTTTTATAATTCGAAAATAATTCTTAGCGTTTATTATTTTC</b>
50	<b>AAAATATTTCTTAGCGTTTATATTTTAAAATATTCTTAGCGTTTATTTTAA</b>
51	<b>AAAATATTTCTTAGCGTTTATATTTTAAAAATATTCTTAGCGTTTATTTTTT</b>
52	<b>AAAATATTTCTTAGCGTTTATATTTT-C2-spacer-TAAAATATTCTTAGCGTTTATTTTAA</b>
53	<b>AAAATATTTCTTAGCGTTTATATTTT-C2-spacer-AAAATATTCTTAGCGTTTATTTTTT</b>
54	<b>AAATTATATCTTAGCGTTTTATAATTTTTTAATATTCTTAGCGTTTATATTAAA</b>
55	<b>AATTATATCTTAGCGTTTTATAATTTTTAATATTCTTAGCGTTTATATTAA</b>
56	<b>AAATTATATTCTTAGCGTTTTATAATTTTTTAATATTCTTAGCGTTTATATTAAA</b>
57	<b>AAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCTTAGCGTTTTATTTTAA</b>

**[0119]** In other embodiments described herein, the aptamer is designed to form a hairpin structure wherein the aptamer is predicted to comprise a single stem having two single strands which are complementary and terminating in a single loop. The single stem in the predicted hairpin structure as described herein comprises a first polynucleotide sequence which is annealed to a third polynucleotide sequence wherein the first and third polynucleotide sequences are complementary and are equal in length. The 3' end of the first polynucleotide sequence is covalently bound to the 5' end of a second polynucleotide sequence which is predicted to form a single stranded loop in the predicted hairpin aptamer, and the 3' end of the second polynucleotide sequence is covalently bound to the 5' end of the third polynucleotide sequence. Table 3 below provides some exemplary oligonucleotide sequences for the first and/or third polynucleotide sequences in the hairpin aptamer. It is understood that any of these sequences may have a nucleotide substitution at 1, 2 3 or 4 positions in the sequence. In

preferred embodiments, the second polynucleotide sequence which is predicted to form a loop comprises TTCTTAGCGTTT (SEQ ID NO:3).

**Table 3**  
**Hairpin Aptamer Stem Sequences**

5

SEQ ID NO	Sequence 5' → 3'
58	TTATTTTAAAAATTATA
59	TATAATTTTAAAAATA
60	TATTTTAAAAAATATA
61	TATATTTTAAAAATA
62	TTAATTTAAATTTATA
63	TATAAATTTAAATTAA
64	TTAATTTTAAAAATATA
65	TATATTTTAAAAATTAA
66	TTATTTTAAAAAATA
67	TATTTTAAAAAATAA
68	TTATATTTAAATTATA
69	TATAATTTAAATATAA
70	TATATTTTAAAAA
71	TAATTTTAAAAATAT
72	TAATTTTAAAAAATA
73	TATTTTAAAAATTA
74	TTATTTTAAAAAAT
75	ATTTTAAAAAATAA
76	TAATTTTAAAAAAT
77	ATTTTAAAAATTA
78	TAATTTTAAAAAT
79	ATTTTAAAAATTA
80	CAATTTTAAAAAT
81	ATTTTAAAAATTG

- [0120]** In some embodiments, the hairpin aptamers have 5' and/or 3' overhangs which represent a full or partial sequence of SEQ ID NO:3 or a variant thereof. An example of a hairpin aptamer according to the present disclosure is provided in FIGS. 3A and 3B. The underlined portion of FIG. 3A indicates the sequence of SEQ ID NO:3. Accordingly, the hairpin aptamer of FIG. 3A has an overhang comprising a 3' portion of SEQ ID NO:3. Specifically, FIG. 3A illustrates a hairpin aptamer in which a 3' portion of SEQ ID NO:3 (GTTT) is ligated to the 5' nucleotide of a stem strand comprising the sequence TTATTTTAAAATTATA (SEQ ID NO:58) and the remaining 5' portion of SEQ ID NO:3 is ligated to the 3' nucleotide of a second stem strand comprising the sequence TATAATTTTAAAATAA (SEQ ID NO:59). Because there is no covalent (phosphodiester) bond between nucleotides 4 and 5 of SEQ ID NO:3, the oligonucleotide of SEQ ID NO:90 (FIG. 3B) is predicted to fold into a hairpin structure as described in FIG. 3A.
- [0121]** To synthesize the hairpin aptamer, oligonucleotides can be chemically synthesized based on the sequences shown in Table 4 below. The underlined bases indicate the 3' and 5' portions of SEQ ID NO:3 (cut loop). The bolded bases indicate stem sequences which are fully complementary to one another and which are predicted to hybridize when the aptamer is folded into a hairpin structure. SEQ ID NO:79 illustrates a hairpin structure in which the 3' overhang represents the full loop sequence of SEQ ID NO:3 while SEQ ID NO:80 illustrates a hairpin structure in which the 5' overhang represents the full loop sequence of SEQ ID NO:3. SEQ ID NO:84 is an example of a hairpin aptamer with a 3' overhang in which a 5' portion of a sequence consisting of SEQ ID NO:3 is covalently linked to the 3' end of one stem sequence, the remaining 3' portion of the sequence consisting of SEQ ID NO:3 is covalently linked to the 5' end of the complementary stem sequence, and there is no covalent (e.g., phosphodiester) bond between nucleotides 7 and 8 of the sequence consisting of SEQ ID NO:3.

**Table 4**  
**Hairpin Aptamer Synthesized as Linear Oligonucleotides**

SEQ ID NO	Sequence 5' → 3'
82	<u>GCGTTTTT</u> <b>TTATTTTAAAATTATA</b> TTCTTAGCGTTTT <b>TATAATTTTAAAATAA</b> <u>TTCTTA</u>
83	<b>TTATTTTAAAATTATA</b> TTCTTAGCGTTTT <b>TATAATTTTAAAATAA</b> <u>TTCTTAGCGTTT</u>

SEQ ID NO	Sequence 5' → 3'
84	<u>TTCTTAGCGTTTTTATTTTAAAATTATATTCTTAGCGTTTTATAATTTTAAAATAA</u>
85	<u>GCGTTTTATAATTTTAAAATAATTCTTAGCGTTTTATTTTAAAATTATATTCTTA</u>
86	<u>TTCTTAGCGTTTTATAATTTTAAAATAATTCTTAGCGTTTTATTTTAAAATTATA</u>
87	<u>TATAATTTTAAAATAATTCTTAGCGTTTTATTTTAAAATTATAATTCTTAGCGTTT</u>
88	<u>CGTTTTTATTTTAAAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCTTAG</u>
89	<u>AGCGTTTTTATTTTAAAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCTT</u>
90	<u>GTTTTTATTTTAAAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCTTAGC</u>
91	<u>TAGCGTTTTTATTTTAAAATTATATTCTTAGCGTTTTATAATTTTAAAATAATTCT</u>
92	<u>GCGTTTTATTTTTAAAAATATATTCTTAGCGTTTTATATTTTTAAAAATAATTCTTA</u>
93	<u>GCGTTTTTAATTTAAATTTATATTCTTAGCGTTTTATAAATTTAAATTAATTCTTA</u>
94	<u>GCGTTTTTAATTTTAAAAATATATTCTTAGCGTTTTATATTTTTAAAAATTAATTCTTA</u>
95	<u>GCGTTTTTATTTTTAAAAAATATTCTTAGCGTTTTATTTTTTAAAAATAATTCTTA</u>
96	<u>GCGTTTTTATATTTAAATTTATATTCTTAGCGTTTTATAATTTAAATATAAATTCTTA</u>
97	<u>CGTTTTTATTTTTAAAAAATATTCTTAGCGTTTTATTTTTTAAAAATAATTCTTAG</u>
98	<u>GTTTTTATTTTTAAAAAATATTCTTAGCGTTTTATTTTTTAAAAATAATTCTTAGC</u>
99	<u>CGTTTATATTTTTAAAAATTTATTCTTAGCGTTTTAATTTTTAAAAATATTCTTAG</u>
100	<u>GTTTATATTTTTAAAAATTTATTCTTAGCGTTTTAATTTTTAAAAATATTCTTAGC</u>
101	<u>GTTTAAATTTTAAAAAATATTCTTAGCGTTTTATTTTTTAAAATTAATTCTTAGC</u>
102	<u>GTTT TTATTTTTAAAAAATTTCTTAGCGTTTATTTTTTAAAAATAATTCTTAGC</u>
103	<u>GTTT TAATTTTAAAAAATTTCTTAGCGTTTATTTTTTAAAATTAATTCTTAGC</u>
104	<u>GTTT TAATTTTAAAAATTTCTTAGCGTTTATTTTTTAAAATTAATTCTTAGC</u>
105	<u>GTTTCAATTTTAAAAATTTCTTAGCGTTTATTTTTTAAAATTGTTCTTAGC</u>

#### Aptamer Inhibition Activity

**[0122]** Also contemplated is a method for reversibly inhibiting polymerase activity comprising incubating an aptamer as described herein with a thermostable polymerase. The aptamers of the present disclosure were  
5 designed to bind to a thermostable polymerase and inhibit the polymerase activity of that polymerase at lower temperatures, then dissociate from the polymerase as the reaction temperature is raised. In some embodiments, the thermostable polymerase is selected from but not limited to DNA polymerases from

thermophilic Eubacteria or Archaeobacteria, including but not limited to, *Thermus aquaticus*, *T. thermophilus*, *T. bockianus*, *T. flavus*, *T. rubber*, *Thermococcus litoralis*, *Pyrococcus furiosus*, *P. wosei*, *Pyrococcus* spec. KGD, *Thermatoga maritime*, *Thermoplasma acidophilus*, and *Sulfolobus* spec. In some

5       embodiments the polymerase may be a reverse transcriptase functional between 55-60° C, including but not limited to, MmLV reverse transcriptase, AMV reverse transcriptase, RSV reverse transcriptase, HIV-1 reverse transcriptase, and HIV-2 reverse transcriptase.

**[0123]** The ability of the aptamer to bind to and inhibit, then dissociate from the  
10       polymerase depends in part upon its secondary structure in the reaction mixture. Aptamers of the present disclosure have melting temperatures ranging from about 45°C to 70°C. In some embodiments, the closed (ligated) dumbbell aptamers have higher melting temperatures, ranging from about 60°C to 70°C, 60°C to 65°C or 65°C to 70°C, while the open dumbbell aptamers lacking a  
15       phosphodiester bond in one strand of the stem have a melting temperature ranging from about 45°C to 55°C, 45°C to 50°C, 50°C to 55°C, or 48°C to 53°C. Melting temperatures are determined in some embodiments at an aptamer concentration of about 8 µM in a buffered solution having a pH of about 8. The buffered solution in some embodiments comprises 3 mM MgCl<sub>2</sub>, 15 KCl, 25 mM  
20       HEPES, pH 8.0. Melting temperatures for each aptamer can be measured using a UV-Vis-NIR spectrophotometer (see, e.g., Example 2).

**[0124]** While the loss of secondary structure of an inhibitory aptamer can result in a decrease in the aptamer's ability to remain bound to and inhibit a  
polymerase, dissociation from the polymerase with increasing temperatures can  
25       depend on other factors such as the primary sequence of the aptamer and the interface between the aptamer and the polymerase. Accordingly, contemplated and described are aptamers that inhibit, reduce or eliminate thermostable polymerase activity at temperatures below about 50°C, 45°C, 44°C, 43°C, 42°C, 41°C, 40°C, 39°C or 38°C. In some embodiments, the aptamer and polymerase  
30       are in a solution having a pH of about 6-8, 6-9, 7-8, 7-9, or 8-9.

**[0125]** The ability of an aptamer to inhibit, reduce or eliminate the polymerase activity of a thermostable polymerase can be measured and quantified using an assay which measures the polymerase activity in the presence or absence of the aptamer at varying temperatures. It is understood that several alternative  
35       methods may be used to measure the ability of an aptamer to inhibit polymerase

activity in a temperature-dependent way, only some of which are briefly described here.

**[0126]** One method for measuring the inhibitory effects of an aptamer on the activity of a thermostable polymerase is exemplified in Example 3 below and further described in Nikiforov et al., 2011, *Analytical Biochemistry*, 412: 229-236. Specifically, a hairpin template is provided in which a fluorescent label (e.g., fluorescein (FAM; 5'-Dimethoxytrityloxy-5-[N-((3',6'-dipivaloylfluoresceinyl)-aminoethyl)-3-acrylimido]-2'-deoxyUridine-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite) dT residue) is incorporated near the 3' end (e.g., 2, 3, 4 or 5 bases away from the 3' end of the oligonucleotide substrate). To a PCR reaction mixture (e.g., 50 mM Tris-HCl, pH 8.3, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, and 2 µL of 2 mM dATP), a polymerase preparation is added wherein the polymerase is in the presence or absence of the inhibitor aptamer. In some embodiments comprising both polymerase and inhibitor aptamer, about 0.8 µM polymerase is mixed with 8 µM aptamer (1:10 ratio). In other embodiments, the polymerase/aptamer ratio is about 1:5 to 1:15 or about 1:5 or 1:15. After addition of polymerase to the PCR reaction mix containing the labeled hairpin substrate, the reaction is heated from about 25°C to 75°C and the FAM signal is measure using a standard dissociation curve program (e.g., Mx3005P, Agilent Technologies) to determine the temperature at which the polymerase is active, and the temperature below which the polymerase is inhibited by the aptamer.

**[0127]** Another method for measuring thermostable polymerase activity in the presence and absence of an aptamer involves use of an oligonucleotide substrate for the polymerase which forms a hairpin structure having a stem and a loop, wherein the stem has a long single-stranded portion which terminates at the 3' end. A quencher (e.g., N,N'-tetramethyl-rhodamine, TAMRA) is attached to the stem near the 5' end of the loop and a fluorescent dye (e.g., carboxyfluorescein, FAM) is attached to the stem near the 3' end of the loop. The fluorescence of the dye is quenched through resonance energy transfer by the quencher when the aptamer substrate is in its predicted folded structure until a oligonucleotide primer is added and allowed to anneal to the 3' end of the stem single-stranded portion and is extended to synthesize the complementary strand by the polymerase, resulting in opening of the loop and spatial separation of the quencher and dye. The polymerase and aptamer are mixed in an appropriate solution of reagents at least including nucleotide triphosphates, a divalent metal cation, an appropriate

buffer and primer and fluorescence is measured over time, with fluorescence increasing at a rate proportional to the polymerase activity. The kinetics of enzymatic DNA synthesis exhibit Michaelis-Menten dependence on substrate concentration. Accordingly, inhibition profiles for various aptamers can be generated by running a series of polymerase reactions in the presence of increasing amounts of aptamer. The resulting data can be used to determine an  $IC_{50}$  value for each aptamer (Summerer and Marx, Angew Chem Int, 2002, 41:3620-3622). Moreover,  $IC_{50}$  values for each aptamer can be determined over a range of temperatures.

10 **[0128]** A third alternative method for measuring the ability of an aptamer as described herein to inhibit a thermostable polymerase in a temperature-dependent manner is by using a template oligonucleotide DNA molecule which is labeled at its 5' end with  $^{32}P$ - $\gamma$ -ATP and which forms a hairpin wherein a 5' portion (e.g., 12-24 nucleotides) of the oligonucleotide is single-stranded followed by a double-stranded stem and small loop. As above, the thermostable polymerase is incubated with varying concentrations of an aptamer as described herein, then added to the substrate and standard PCR reaction mixture and the PCR reaction is allowed to proceed for a set period of time (e.g., 45 min. to 1 hour) at different temperatures (e.g., 25°C to 75°C), stopped by the addition of EDTA, and then resolved using polyacrylamide gel electrophoresis. Standard phosphorimager detection and quantitation methods can be used to determine polymerase activity level as only when the polymerase is active (not inhibited by the aptamer at a given temperature) will the 3' end of the hairpin substrate be extended to form a longer product which is radio-labeled and detected. As with the assays above, an  $IC_{50}$  for each aptamer at a given temperature can be determined by quantitation and analysis.

25 **[0129]** The use of the aptamers described herein for hot start polymerase applications which can decrease nonspecific product generation relies on the ability of the aptamer to dissociate from the polymerase as the temperature. Accordingly, an aptamer according to the present disclosure dissociates from a thermostable polymerase when a reaction mixture containing the aptamer and the polymerase is raised to a temperature of at least about 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, or 80°C. As a loss of inhibition of the polymerase is a likely indication of aptamer dissociation from the polymerase, in other embodiments, a reversibly inhibitory aptamer of the present disclosure does not

30

35

inhibit thermostable polymerase activity when the reaction mixture containing the aptamer and the polymerase is raised to a temperature of at least about 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, or 80°C. It is understood that the temperature above which an aptamer no longer inhibits polymerase activity

5 depends on the sequence, composition and inherent structure of the aptamer in solution with the polymerase. Accordingly, any aptamer sequence as described herein may be further characterized or defined by its lack of polymerase activity inhibition at or above a specified temperature.

**[0130]** Moreover, any aptamer sequence and predicted structure as described  
10 herein may be further characterized or defined by its ability to inhibit polymerase activity at or below a specified temperature. In some embodiments, the aptamer inhibits the polymerase by 95%-100%, 98% to 100% or by about 100% relative to polymerase activity in the absence of the aptamer at or below a temperature of about 25°C, 30°C, or 35°C. As the temperature of the mixture containing the  
15 aptamer and the polymerase is raised, there will be a corresponding loss of inhibition. Experimental studies suggest that a transition from about 95% to 100% of polymerase activity to loss of substantially all inhibition can occur over a temperature range of about 4°C to 10°C, or 5°C to 7°C.

Inhibition of polymerase activity by an aptamer as described herein can also be  
20 affected by the concentration of the aptamer and polymerase in a mixture or by the ratio of aptamer:polymerase. For example, the aptamer is effective in inhibiting polymerase activity when the aptamer is present in the mixture at a concentration of about 100 nM to 1000 nM, 100 nM to 500 nM, 25 nM to 750 nM, for 500 nM to 1000 nM. The aptamers described are useful for reversibly  
25 inhibiting thermostable polymerases including DNA polymerases, RNA polymerases and reverse transcriptases.

**[0131]** The ability of the aptamers provided herein to inhibit polymerase activity at ambient temperatures or at temperatures lower than temperatures which are optimal for polymerase activity is advantageous for at least the reason that there  
30 will be a decrease in or elimination of non-specific products generated at these lower temperatures. As shown at least in Examples 4 and 5 and FIGS. 4-5, use of the aptamers can reduce generation of non-specific products and increase production of the target amplicon(s).



Applications

**[0132]** As described above, aptamers of the present disclosure have the ability to reversibly inhibit thermostable polymerases at ambient temperatures or temperatures below the optimal temperatures for various thermostable polymerases. These aptamers thus can readily be applied to any applications wherein a thermostable nucleotide polymerase is used and wherein it is desirable to have the polymerase activity turned off at a lower temperature but then be able to regain its activity at a higher temperature (hot start). Such applications include but are not limited to standard PCR, reverse transcriptase PCR, in-situ PCR, quantitative PCR, and minisequencing or other reactions involving primer extension in which a thermostable polymerase present and a hot-start method is advantageous. Such methods are well known in the art. In some embodiments, the increased sensitivity and specificity provided by the disclosed compositions is useful during the amplification and analysis of DNA and RNA in medical genetics research and diagnosis, pathogen detection, forensic analysis, and animal and plant genetics applications. The methods and compositions of the present disclosure are useful in any polynucleotide synthesis reaction that requires thermostable polymerase to cycle anywhere between 40°C and 80°C.

**[0133]** Examples 4 and 5 below describe PCR experiments performed using Taq polymerase in the presence or absence of an aptamer according to the present disclosure. These studies demonstrate the ability of the aptamers described herein to both decrease generation of non-specific amplification products as well as increase quantities of target amplicons in the reaction mix. Example 4 describes a bplex PCR reaction containing genomic DNA and 2 primer pairs for amplification of two target sequences. Prior to initiating a PCR reaction by addition of the thermostable polymerase, 4 units of Taq polymerase was incubated with 200 nM prior to adding the Taq to the PCR master mix. In this particular experiment, an unligated (open) dumbbell aptamer was used which was shown (Example 2) to have a melting temperature of about 42°C. Detection and analysis of fluorescence signals as well as gel analysis of the PCR products show effects on both non-specific product generation and on the quantity of target amplicon production. It is contemplated that any of the aptamers described herein which have melting temperatures below the optimal temperature of the thermostable polymerase in the reaction mix can enhance target amplicon generation and detection.

**[0134]** Example 5 explores varying ratios of aptamer:thermostable polymerase on non-specific product and target amplicon generation. Ratios ranging from about 2.5:1 to 15:1 were tested. While all ratios resulting in generation of the desired product, the 15:1 ratio was most effective in reducing non-specific product generation while maintaining levels of target amplicon generation.

**[0135]** Accordingly, contemplated herein are methods which involve using a thermostable polymerase to extend a primer which is annealed to a nucleotide template or substrate molecule. As well understood in the art, wherein the primer is extended by the polymerase in the presence of nucleotides (e.g., the deoxyribonucleotides, dATP, dGTP, dCTP, dTTP), a divalent metal cation such as  $Mg^{2+}$  or  $Mn^{2+}$ , a buffer, and at least one primer.

**[0136]** In some embodiments, the inhibitors described herein may be used in combination with other hot-start technologies such as antibody-based hot start. In other embodiments, for example, two or more aptamers which dissociate from a polymerase at different temperatures may be combined in a single reaction.

#### Exemplary Automation and Systems

**[0137]** In some embodiments, a target nucleic acid sequence is copied or amplified, then detected using an automated sample handling and/or analysis platform. In some embodiments, commercially available automated analysis platforms are utilized. For example, in some embodiments, the GeneXpert® system (Cepheid, Sunnyvale, Calif.) is utilized.

**[0138]** The present disclosure is illustrated for use with the GeneXpert system. Exemplary sample preparation and analysis methods are described below. However, the present disclosure is not limited to a particular detection method or analysis platform. One of skill in the art recognizes that any number of platforms and methods may be utilized.

**[0139]** The GeneXpert® utilizes a self-contained, single use cartridge. Sample extraction, amplification, and detection may all be carried out within this self-contained "laboratory in a cartridge." (See e.g., U.S. Pat. Nos. 5,958,349, 6,403,037, 6,440,725, 6,783,736, 6,818,185; each of which is herein incorporated by reference in its entirety.)

**[0140]** Components of the cartridge include, but are not limited to, processing chambers containing reagents, filters, and capture technologies useful to extract, purify, and amplify target nucleic acids. A valve enables fluid transfer from

chamber to chamber and contains nucleic acids lysis and filtration components. An optical window enables real-time optical detection. A reaction tube enables very rapid thermal cycling.

5     **[0141]** In some embodiments, the GenXpert® system includes a plurality of modules for scalability. Each module includes a plurality of cartridges, along with sample handling and analysis components.

10    **[0142]** After the sample is added to the cartridge, the sample is contacted with lysis buffer and released DNA is bound to a DNA-binding substrate such as a silica or glass substrate. The sample supernatant is then removed and the DNA eluted in an elution buffer such as a Tris/EDTA buffer. The eluate may then be processed in the cartridge to detect target genes as described herein. In some embodiments, the eluate is used to reconstitute at least some of the PCR reagents, which are present in the cartridge as lyophilized particles.

15    **[0143]** In some embodiments, PCR is used to amplify and detect the presence of the target nucleic acid sequence and/or a nucleic acid sequence that indicates genomic copy number. In some embodiments, the PCR uses Taq polymerase with hot start function imparted by use of an aptamer as provided herein.

#### Kits

20    **[0144]** Kits for detecting a nucleic acid target sequence present in solid, semi-solid, or liquid biological samples are also provided. The kit includes a reagent mix comprising a thermostable polymerase and an aptamer as described herein that can reversibly inhibit activity of the polymerase. In some embodiments, the kit can be used for detection, quantifying or sequencing any target nucleic acid. Alternatively, the kit includes one or more oligonucleotide primers (e.g., a forward  
25    and/or reverse primer) that specifically hybridize to a specified target nucleic acid and may also include labeled primers and/or probes as is routine in the art.

30    **[0145]** The kits may include instructions for obtaining biological samples and contacting them with sample buffer, for mixing the samples with sample buffer, placing labels on the apparatus and recording relevant test data; for shipping the apparatus, and the like. The kits may include instructions for reading and interpreting the results of an assay. The kits may further comprise reference samples that may be used to compare test results with the specimen samples.

## EXAMPLES

## Example 1

## Oligonucleotide Synthesis and Ligation

**[0146]** Aptamers as described herein were synthesized using standard  
5 oligonucleotide synthesis methods. Oligonucleotide synthesis was performed on a MerMade 12 DNA Synthesizer (BioAutomation). Standard phosphoramidite synthesis cycles were used, and coupling time was increased to 360 seconds for modified phosphoramidites. Cleavage from the solid support and deprotection was carried in concentrated aqueous ammonia at RT for 24 hrs. HPLC analyses  
10 were done on an Agilent 1100 instrument equipped with a quaternary pump, autosampler, and diode array detector. Oligonucleotides were analyzed using reversed-phase HPLC (RP HPLC) on a C18 Gemini column (4.6 mmX250 mm, 5 um, Phenomenex) eluting with a linear gradient of acetonitrile/0.1 M triethylammonium bicarbonate, pH 7: 16-23% acetonitrile over 20 min for DMT-on  
15 oligonucleotides and 7-14% acetonitrile for oligonucleotides with DMT groups removed (DMT-off). DMT-on oligonucleotides were purified using reverse phase HPLC, DMT groups were cleaved, and the final oligonucleotide products were isolated by ethanol precipitation and quantified by UV.

**[0147]** Where indicated, some aptamers were modified at the 5' and/or 3' end  
20 after synthesis. 5' and 3' phosphorylation was achieved using (3-(4,4'-Dimethoxytrityloxy)-2,2-(dicarboxymethylamido)propyl-1-O-succinoyl-long chain alkylamino-CPG) (Glen Research Cat. No. 10-1901; U.S. Pat. No. 5,959,090 and EP Pat. No. EP0816368) and (3-(4,4'-Dimethoxytrityloxy)-2,2-dicarboxyethyl]propyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen  
25 Research Cat. No. 20-2903; U.S. Pat. No. 5,959,090). Modification of the 5' end with an amino group was achieved using 5'-Amino-dT-CE Phosphoramidite (Glen Research Cat. No. 10-1932), (5'-monomethoxytritylamino-2'-deoxyThymidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite). Modification of the 3' end with a propanediol spacer CPG (-C3) was achieved using ((1-Dimethoxytrityloxy-  
30 propanediol-3-succinoyl)-long chain alkylamino-CPG) (Cat. No. 20-2913).

**[0148]** To produce ligated dumbbell aptamers, oligonucleotides synthesized as above were ligated either enzymatically or chemically. For enzymatic ligation, 1 mL of 16 µM 5'-phosphate-modified oligonucleotide in a 50 mM KCl solution was heated to 95°C for 5 min in a heating block and slowly cooled to room  
35 temperature in the same heating block by switching the power off to allow

annealing (intramolecular hybridization) of the oligonucleotide. 900  $\mu$ L of the annealed oligonucleotide was mixed with 100  $\mu$ L T4 ligation buffer, then with 10  $\mu$ L T4 ligase (New England BioLabs) and left overnight at 16°C. Ligated aptamer was purified by RP-HPLC method.

- 5 **[0149]** To produce chemically ligated aptamers, 5' ((amino)-T))-modified oligonucleotide (220  $\mu$ M) in 5 mM HEPES-KOH buffer pH 7.5 and 50 mM KCl was denatured at 95°C for 5 min. followed by slow (approximately 1 hr) cooling-annealing to room temperature. Then 100  $\mu$ L of annealed oligonucleotide was mixed with 66.7  $\mu$ L 0.1 M imidazole-HCl (pH 6.0) and 16.7 mg EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide). After a brief vortexing and centrifugation, an  
10 additional 266  $\mu$ L of 0.1 M imidazole-HCl (pH 6.0) was supplied to the reaction and mix was left overnight at room temperature. Ligated oligonucleotide was purified by RP-HPLC.

## Example 2

### Melting Temperature (T<sub>m</sub>) Determination

- 15 **[0150]** UV-melt curve analysis was performed for various aptamers generated according to Example 1 above. Oligonucleotides were prepared at a concentration of 1  $\mu$ M in buffer (3 mM MgCl<sub>2</sub>, 15 KCl, 25 mM HEPES, pH 8.0) and analyzed using an Agilent Technologies Cary 4000 Series UV-Vis-NIR  
20 spectrophotometer and associated software according to the manufacturer's instructions. Results are presented below in Table 5. As expected, the T<sub>m</sub>'s of unligated dumbbell aptamers are lower than T<sub>m</sub>'s of the ligated dumbbell aptamers.

**Table 5**

25

SEQ ID NO	T <sub>m</sub> (°C)	Description	Linear Oligonucleotide Sequence (5' → 3') (including terminal modifications if present)
54	63.1	Ligated (closed) dumbbell	AAATTATATCTTAGCGTTTTATAATTTTAAATATTCTTAGCGTTTATATTAA
55	60.2	Ligated (closed) dumbbell	AATTATATCTTAGCGTTTTATAATTTTAAATATTCTTAGCGTTTATATTAA
56	62.7	Ligated (closed) dumbbell	AAATTATATTCTTAGCGTTTTATAATTTTAAATATTTCTTAGCGTTTATATTAA
95	55.3	hairpin	GCGTTTTTATTTTAAAAAATATTCTTAGCGTTTTATT TTTAAAAATAATTCTTA-C3
96	52.9	hairpin	GCGTTTTTATTTTAAATTATATTCTTAGCGTTTTATA ATTTAAATATAATTCTTA-C3
97	55.5	hairpin	CGTTTTTATTTTAAAAAATATTCTTAGCGTTTTATTT TTTAAAAATAATTCTTAG-C3
98	55.5	hairpin	GTTTTTATTTTAAAAAATATTCTTAGCGTTTTATTT TTTAAAAATAATTCTTAGC-C3

SEQ ID NO	T <sub>m</sub> (°C)	Description	Linear Oligonucleotide Sequence (5' → 3') (including terminal modifications if present)
99	56.6	hairpin	CGTTTATATTTTTTAAAAATTATTTCTTAGCGTTTAAATT TTTAAAAATATTTCTTAG-C3
57	63	Ligated (closed) dumbbell	AAATTATATTTCTTAGCGTTTATAATTTTAAAAATAATT CTTAGCGTTTTATTTTA
88	55.0	hairpin	CGTTTTTATTTTTTAAAAATTATATTTCTTAGCGTTTTATAA TTTTAAAAATAATTCTTAG-C3
89	54.4	hairpin	TAGCGTTTTTATTTTTTAAAAATTATATTTCTTAGCGTTTTTA TAATTTTAAAAATAATTCT-C3
90	54.6	hairpin	GTTTTTATTTTTTAAAAATTATATTTCTTAGCGTTTTTATAAT TTTAAAAATAATTCTTAGC-C3
91	54.4	hairpin	TAGCGTTTTTATTTTTTAAAAATTATATTTCTTAGCGTTTTTA TAATTTTAAAAATAATTCT-C3
92	55.2	hairpin	GCGTTTTTATTTTTTAAAAATATATTTCTTAGCGTTTTTATA TTTTTAAAAATATTTCTTA-C3
93	54.5	hairpin	GCGTTTTTAAATTTAAATTTATATTTCTTAGCGTTTTTATA AATTTAAATTAATTCTTA-C3
94	55.2	hairpin	GCGTTTTTAAATTTTAAAAATATATTTCTTAGCGTTTTTATA TTTTAAAAATTAATTCTTA-C3
100	56.2	hairpin	GTTTATATTTTTTAAAAATTATTTCTTAGCGTTTTTAATTT TTAAAAATATTTCTTAGC-C3
44	45.0	Non-ligated dumbbell	(amino) - TAAAAATAATTCTTAGCGTTTTTATTTTTAAAAATTATAT TCTTAGCGTTTTTATAATTT-p
44	42	Non-ligated dumbbell	TAAAAATAATTCTTAGCGTTTTTATTTTTAAAAATTATAT CTTAGCGTTTTTATAATTT-C3

### Example 3

#### Polymerase Inhibition

- 5 **[0151]** Studies are done to measure the inhibitory activity of aptamers described herein as a function of temperature. Polymerase activity of Taq polymerase in the presence of aptamers is assayed by a method described in the art (Nikiforov T., *Analytical Biochemistry*, 412: 229-236 (2011) with the following modification. Because the aptamers of the present invention inhibit Taq
- 10 polymerase activity above ambient temperature, the structure of the hairpin substrate is modified to increase its T<sub>m</sub>. Hairpin substrate TTTTTTGCAGGTGACAGGCGCGAAGCGCCTGTCACXGC (SEQ ID NO: 6), wherein X denotes a fluorescein dT residue is used in the assay. To a solution of 150 nM of the hairpin substrate in 50 mM Tris-HCl, 50 mM NaCl, 5 mM MgCl<sub>2</sub>,
- 15 and Taq polymerase, 2 μL of 2 mM dATP is added, and the FAM signal is monitored while the reaction mixture is heated from 25°C to 74°C using the standard dissociation curve program (Mx3005P, Agilent). The assays measure the reversible inhibition activity of the aptamers whereby polymerase activity is regained upon heating of the reaction mixture. The temperature at which
- 20 inhibition is lost depends on the sequence and structure of the aptamer.

#### Example 4

##### Hot Start Activity

**[0152]** To test the ability of aptamers designed as described herein to reduce non-specific product generation in a PCR reaction, a human genomic biplex PCR amplification assay was performed in which two regions of the beta-globin gene were detected followed by post-PCR melt curve analysis using Eva-Green. The two primer pairs had the sequences:

AAAAGGCATTCCTGAAGCTGACAGCATTC (SEQ ID NO:7, forward primer 1) and GAGAGAGTAGCGCGAGCACAGCTA (SEQ ID NO:8, reverse primer 1); and

AAAACCTGCCTTCTGCGTGAGATTCT (SEQ ID NO:9, forward primer 2) and CTGTACGAAAAGACCACAGGGCCCAT (SEQ ID NO:10, reverse primer 2). The PCR master mix, prepared at room temperature, contained 100  $\mu$ M dNTPs, 5 mM  $MgCl_2$ , 25 mM HEPES, pH 8.5, X1 EvaGreen® (1X concentration), human genomic DNA (1000 copies/reaction), 0.30% Tween 20, and 1 mg/mL BSA. 4 u

Taq DNA polymerase (GMP Taq, Roche Diagnostics) was added to each reaction from a 0.25 u/ $\mu$ L preparation. An aptamer comprising CAAAATAATTCTTAGCGTTTTTATTTTGCAATTATTTCTTAGCGTTTTATAATT G-C3 (SEQ ID NO:106) was added to selected reactions at a concentration of 200 nM. The reactions were initiated by the addition of Taq or Taq plus aptamer.

Where aptamer was included in the reaction, the Taq and aptamer were premixed at room temperature just prior to addition to the PCR master mix. The Stratagene Mx3005P 96 well-plate system (Agilent Technologies) was used to run and analyze the PCR reactions. Cycling conditions were as follows: 95°C for 100 s, 45 cycles of 95°C for 8 s and 68°C for 30 s, then 95°C for 10 s, 60°C for 30 s, concluding with melt curve analysis at 60°C to 95°C over a 20 min period.

**[0153]** Results in which product generation measured by an increase in fluorescence vs. cycle number (FIGS. 4A and 4B) show that presence of the aptamer (FIG. 4B) resulted in higher product generation compared to absence of the aptamer (FIG. 4A). Melt curve analysis (FIGS. 5A and 5B) showed that the two specific bands corresponding to the beta-globin amplicons were detected in reactions both with and without aptamer but were not detected in reactions lacking Taq polymerase. Moreover, FIGS. 5A and 5B demonstrate a significant decrease in the generation of non-specific products in reactions containing Taq polymerase and aptamer as compared to reactions run in the absence of aptamer. The data show that quantities of the specific beta-globulin amplicons

were higher in reactions containing both Taq and the aptamer. (Lane 1: molecular weight markers; corresponding bp values are to the left and right of the gel image; Lanes 2, 3, 6, 7, 8, 9: Taq and aptamer only without PCR master mix; Lanes 4, 10, 11: PCR master mix with Taq with no aptamer; Lanes 5, 12, 13: PCR master mix with Taq and aptamer.)

### Example 5

#### Hot Start PCR

**[0154]** As described herein, aptamers can reversibly inhibit polymerase activity at temperatures below the optimal reaction temperature for the polymerase.

Studies were done to evaluate the effects of varying aptamer:Taq (*T. aquaticus* DNA polymerase) ratios using the Xpert® *C. difficile*/Epi Assay (Cepheid), and to determine an optimal aptamer:Taq ratio with respect to target product and non-specific product generation. The aptamer used in the present example is the aptamer described herein as SEQ ID NO:106

(CAAATAATTCTTAGCGTTTTTATTTTGCAATTATATTCTTAGCGTTTTATAAT TG-C3), modified at its 3' end with a propanediol spacer CPG as described in Example 1.

**[0155]** Live *C. difficile* cells at 3 concentrations (275, 92, or 23 CFU/test) in a human stool background matrix were used in the assay. The experiment was run in open cartridges on the GeneXpert® instrument with all wet master mixes prepared on the day of the experiment. 48 units of Taq polymerase was used in each reaction and were run in parallel with an AptaTaq® control (Roche Diagnostics). All solutions of Aptamer:Taq were stored in 10% glycerol. Aptamer:Taq ratios of 2.5:1, 5:1, 10:1 and 15:1 were tested. Eight replicates were run for each condition. At the end of the GeneXpert® runs, amplicon was collected from the PCR tubes of the cartridges and evaluated in an Agilent DNA 1000 chip via the 2100 Agilent Bioanalyzer (Agilent Technologies). Only the 1x LoD (equivalent to 92 CFU/test) samples were selected to be evaluated in duplicates in the Agilent system.

**[0156]** Amplicon lengths for the targets of interest are as follow: 81 bp for toxin B (*tcdB*), 91 bp for *tcdC* deletion nt 117, 133 bp for SPC (sample-processing control) and 143 bp for binary toxin (*cdt*). Non-specific bands at 210 bp were observed in all reaction mixtures tested but were the faintest for the 15:1



Aptamer:Taq ratio. The non-specific bands at 210 and 400 bp were the most prominent for the 2.5:1 Aptamer:Taq ratio (data not shown).

**[0157]** Furthermore, the binary toxin end points increased as the amount of non-specific binding decreased (data not shown). The lowest binary toxin end points were observed with the 2.5:1 Aptamer:Taq ratio. The highest binary toxin end points were observed with the 15:1 Aptamer:Taq ratio. This suggests that more of the target binary toxin product was made when non-specific amplification was limited. The results of this study suggest that an Aptamer:Taq ratio of 15:1 for the aptamer comprising SEQ ID NO:106 is optimal for hot start PCR methods using *T. aquaticus* DNA polymerase.

## IT IS CLAIMED:

1. An aptamer comprising in a 5' to 3' direction:
  - a first sequence comprising SEQ ID NO:1 or a variant thereof or SEQ ID NO:2 or a variant thereof,
  - 5 a second sequence comprising SEQ ID NO:3 or a variant thereof,
  - a third sequence comprising SEQ ID NO:1 or a variant thereof or SEQ ID NO:2 or a variant thereof,
  - and a fourth sequence comprising SEQ ID NO:3 or a variant thereof,wherein each of the first and third sequences are 14-18 nucleotides in length,  
10 are equal in length to each other, and are 100% complementary to each other along their entire length; and  
wherein the second and fourth sequences are 12 nucleotides in length and are identical to each other.
- 15 2. The aptamer of claim 1, wherein there is a covalent bond between the 5' end of the first sequence and the 3' end of the fourth sequence.
3. The aptamer of claim 2, wherein the covalent bond is a phosphodiester bond.
- 20 4. The aptamer of claim 2 or 3, wherein there is no covalent bond between 2 of the nucleotides within the first sequence and wherein the aptamer comprises a 5' terminus and a 3' terminus.
5. The aptamer of claim 2 or 3, wherein there is no covalent bond between 2 of  
25 the nucleotides within the third sequence and wherein the aptamer comprises a 5' terminus and a 3' terminus.
6. The aptamer of claim any one of claims 2 to 5, wherein the first sequence comprises SEQ ID NO:1, the third sequence comprises SEQ ID NO:2, and  
30 there is no covalent bond between nucleotides 8 and 9 of SEQ ID NO:1.
7. The aptamer of claim any one of claims 2 to 5, wherein the first sequence comprises SEQ ID NO:2, the third sequence comprises SEQ ID NO:2, and  
there is no covalent bond between nucleotides 8 and 9 of SEQ ID NO:2.

35

8. The aptamer of any one of claims 1 to 6, wherein the first sequence comprises SEQ ID NO:2 and the third sequence comprises SEQ ID NO:3.
9. The aptamer of any one of the preceding claims, wherein the first and third sequences are hybridized to each other along the entire length of each of the first and third sequences.
10. The aptamer of claim 9, wherein there are no mismatches between the first and third sequences.
11. The aptamer of claim 6, wherein the aptamer comprises SEQ ID NO:106.
12. The aptamer of claim 7, wherein the aptamer comprises SEQ ID NO:110.
13. The aptamer of any one of claims 4 to 10, wherein the 5' terminus is phosphorylated.
14. The aptamer of any one of claims 4 to 13, wherein the 3' terminus is linked to a 3' capping moiety.
15. The aptamer of any one of claims 4 to 13, wherein the 5' terminus is linked to a 5' capping moiety.
16. The aptamer any one of claims 4 to 13, wherein the 3' terminus is linked to a 3' capping moiety and the 5' terminus is linked to a 5' capping moiety.
17. The aptamer of claim 14 or 16, wherein the 3' capping moiety is a propanediol spacer (C3) or a phosphate.
18. The aptamer of claim 15 or 16, wherein the 5' capping moiety is an amino group.
19. An aptamer comprising an oligonucleotide comprising in a 5' to 3' direction: a first polynucleotide sequence comprising SEQ ID NO:4 or a variant thereof or SEQ ID NO:5 or a variant thereof,

a second polynucleotide sequence comprising SEQ ID NO:3 or a variant thereof, and

a third polynucleotide sequence comprising SEQ ID NO:5 or a variant thereof or SEQ ID NO:4 or a variant thereof, and

5 a fourth polynucleotide sequence comprising SEQ ID NO:3 or a variant thereof,

wherein each of the second and fourth sequences are 14-20 nucleotides in length, are equal in length, and are complementary to each other along their entire length; and wherein the aptamer comprises a 5' end and a 3' end.

10

20. The aptamer of claim 19, wherein the aptamer comprises an oligonucleotide comprising SEQ ID NO:83 or 87.

15 21. The aptamer of claim 19, wherein the 3' end of the fourth sequence is covalently bound to the 5' end of the first sequence and there is no phosphodiester bond between the last nucleotide of the third sequence and the first nucleotide of the fourth sequence.

20 22. The aptamer of claim 21, wherein the aptamer comprises an oligonucleotide comprising SEQ ID NO:84 or 86.

23. The aptamer of claim 19, wherein the 3' end of the fourth sequence is covalently bound to the 5' end of the first sequence and there is no phosphodiester bond between 2 nucleotides within the fourth sequence.

25

24. The aptamer of claim 23 or 21, wherein there is no phosphodiester bond between nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11 or 11 and 12 of SEQ ID NO:3 in the fourth sequence.

30

25. The aptamer of claim 23 or 24, wherein the aptamer comprises an oligonucleotide comprising one of SEQ ID NOs:82, 85 or 88-105.

26. An aptamer comprising a sequence selected from the group consisting of  
SEQ ID NO:82-105.
27. The aptamer of any one of claims 19 to 26, wherein the 5' end of the aptamer  
5 is linked to a 5' capping moiety.
28. The aptamer of any one of claims 19 to 27, wherein the 3' end of the aptamer  
is linked to a 3' capping moiety.
- 10 29. The aptamer of claim 27 or 28, wherein the 5' capping moiety is an amino  
group.
30. The aptamer of claim 28 or 29, wherein the 3' capping moiety is a propanediol  
spacer (C3) or a phosphate.
- 15 31. The aptamer of any one of the preceding claims, wherein the aptamer does  
not inhibit reverse transcriptase activity.
32. A composition comprising an aptamer according to any one of claims 1 to 31  
20 and a thermostable polymerase.
33. The composition of claim 32, wherein the polymerase is selected from the  
group consisting of *Thermus aquaticus*, *Thermus thermophilus*, or *Thermus*  
*maritima*.
- 25 34. The composition of claim 32 or 33, further comprising deoxyribonucleotide  
triphosphates and a divalent metal cation.
35. The composition of any one of claims 32 to 34, further comprising a forward  
30 primer specific for a target nucleic acid.
36. The composition of any one of claims 32 to 35, further comprising a reverse  
primer specific for the target nucleic acid.

37. The composition of any one of claims 32 to 36, wherein the ratio of the aptamer to the polymerase ranges from about 5:1 to 20:1.
38. The composition of any one of claims 32 to 37, wherein the composition is a dried composition.
39. The composition of claim of any one of claims 32 to 37, wherein the composition is a liquid composition.
40. A method for extending a primer, comprising:  
contacting a sample which might contain a target nucleic acid with a reagent composition to generate a reaction mixture, wherein the reagent composition comprises an aptamer according to any one of claims 1 to 31, a thermostable polymerase, a forward primer specific for the target nucleic acid, deoxyribonucleotide triphosphates, and a divalent metal cation.
41. The method of claim 40, wherein the reagent composition further comprises a reverse primer specific for the target nucleic acid.
42. The method of claim 40 or 41, wherein the reagent composition further comprises a reverse transcriptase and wherein the method further comprises performing a reverse transcriptase reaction prior to heating the reaction mixture.
43. The method of any one of claims claim 40 to 42, wherein the DNA polymerase is selected from the group consisting of *Thermus aquaticus*, *Thermus thermophilus*, or *Thermus maritima*.
44. The method of any one of claims 40 to 43, wherein the ratio of the aptamer to the polymerase ranges from about 5:1 to 20:1.
45. A kit comprising a composition comprising an aptamer according to any one of claims 1 to 31 and a thermostable polymerase.

46. The kit of claim 45, further comprising deoxyribonucleotide triphosphates and a divalent metal cation.
47. The kit of claim 45 or 46, wherein the composition is a dried composition.
- 5 48. The kit of any one of claims 45 to 47, further comprising an aqueous buffer.
49. The kit of any one of claims 45 to 48, wherein the composition further comprises a forward primer specific for a target nucleic acid.
- 10 50. The kit of any one of claims 45 to 49, wherein the composition further comprises a reverse primer specific for the target nucleic acid.
51. The kit of any one of claims 45 to 50, further comprising a reverse
- 15 transcriptase.

TTCTT ATATTACGTTTATT TTTCG  
A  
G CGTTT TATAATTGCAAAATAA TTCTT  
A

FIG. 1A

5' -CAATTATTTAGCGTTTATAAATGCAAAATAATTCTTAGCGTTTATTATTG-3'  
(SEQ ID NO:110)

FIG. 1B






FIG. 2A



FIG. 2B

3'-CGATTCTTAATAAAATTTAATAATTTTGC  
5'-GTTTATTTTAAAAATTATAATTTCTT  
(SEQ ID NO:90)

FIG. 3A

5'-GTTTTATTAAAAATTATAATCTTAGCGTTTATAATTTAAATAATCTTAGC-3'  
(SEQ ID NO:90)

FIG. 3B





FIG. 4A






FIG. 5A




FIG. 5B

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2017/036225

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C12N15/115  
ADD. C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YAKIMOVICH O Y ET AL: "Influence of DNA aptamer structure on the specificity of binding to Taq DNA polymerase", BIOCHEMIS, MAIK NAUKA - INTERPERIODICA, RU, vol. 68, no. 2, 1 February 2003 (2003-02-01), pages 228-235, XP008113189, ISSN: 0006-2979, DOI: 10.1023/A:1022609714768 cited in the application	1-51
Y	the whole document ----- -/--	1-18



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

1 August 2017

Date of mailing of the international search report

14/08/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Spindler, Mark-Peter

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2017/036225

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DI GIUSTO D A ET AL: "Construction, stability, and activity of multivalent circular anticoagulant aptamers", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 45, 5 November 2004 (2004-11-05), pages 46483-46489, XP002600154, ISSN: 0021-9258, DOI: 10.1074/JBC.M408037200 [retrieved on 2004-08-18] the whole document	1-18
A	----- WO 2015/091720 A1 (ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; ROCHE MOLECULAR S) 25 June 2015 (2015-06-25) figure 1; example 1	1-51
A	----- WO 00/52207 A1 (NEXSTAR PHARMACEUTICALS INC [US]) 8 September 2000 (2000-09-08) cited in the application the whole document -----	1-51



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/036225

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015091720	A1	25-06-2015	CA 2930926 A1 25-06-2015
		CN 105874069 A 17-08-2016	
		EP 3083961 A1 26-10-2016	
		JP 2016540517 A 28-12-2016	
		US 2015176059 A1 25-06-2015	
		WO 2015091720 A1 25-06-2015	
-----			
WO 0052207	A1	08-09-2000	AT 478157 T 15-09-2010
		AU 781567 B2 02-06-2005	
		CA 2362526 A1 08-09-2000	
		DK 1171632 T3 08-11-2010	
		EP 1171632 A1 16-01-2002	
		EP 2241635 A1 20-10-2010	
		ES 2349213 T3 29-12-2010	
		HK 1044803 A1 29-04-2011	
		JP 4738599 B2 03-08-2011	
		JP 2002537825 A 12-11-2002	
		JP 2011103890 A 02-06-2011	
		PT 1171632 E 24-11-2010	
		US 6183967 B1 06-02-2001	
		WO 0052207 A1 08-09-2000	
-----			